Historically, says Feinberg, heavily marketed new entrants help all the drugs in a category--and the multiple sclerosis market is still poorly penetrated.
New York ranks 24th in the salary-adjusted cost of living category (the big paychecks help some, but clearly not enough), and San Francisco ranks 17th.